Johnson & Johnson
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
J&J’s second-in-command to retire, alongside executive restructure
June 25, 2018Medical Communications, Sales and Marketing J&J, JJ, Johnson & Johnson, pharma
Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the …
J&J continues to shed assets, with $2.1bn diabetes unit sale
June 13, 2018Research and Development, Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
Just last week, Johnson & Johnson announced that it had received an offer from Fortive for its medical sterilisation unit, …
J&J looks to trim business with $2.8bn sale
June 7, 2018Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
Johnson & Johnson continues to look at options to slim down its business, after having received an offer from Fortive …
Celgene bring in new CFO to steady the ship
June 4, 2018Medical Communications, Sales and Marketing Celgene, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …
J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex
May 29, 2018Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq
Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …
J&J’s ketamine-based antidepressant showed mixed success at Phase 3
May 8, 2018Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma
Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …
J&J’s ketamine nasal spray for depression continues to impress
April 16, 2018Research and Development, Sales and Marketing Johnson & Johnson, Ketamine, biotech, drugs, pharma, pharmaceutical
New treatments for depression are few and far between; pharmaceutical companies have shied away from trying to develop new therapeutics …
Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA
April 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma
Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …
J&J pays out $37m in damages over claims its talc contains asbestos
April 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc
Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …
J&J’s longest-standing CFO finally steps down
March 21, 2018Medical Communications, Research and Development J&J, JJ, Johnson & Johnson, biotech, cfo, drugs, pharma, pharmaceutical
Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from …
FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer
February 9, 2018Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma
Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …
Theravance seals potential $1bn deal with J&J
February 8, 2018Sales and Marketing Johnson & Johnson, Theravance Biopharma, biotech, drugs, pharma, pharmaceutical
The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted …
J&J’s apalutamide shows strength in non-metastatic prostate cancer
February 7, 2018Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer
Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …
US court upholds ruling that J&J’s Remicade patent is invalid
January 24, 2018Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma
The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …
Latest content
Five Facts about cardiovascular disease
